Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C26H27NO10.ClH |
Molecular Weight | 549.954 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.[H][C@@]1(C[C@H](N)[C@H](O)[C@H](C)O1)O[C@H]2C[C@@](O)(CC3=C(O)C4=C(C(=O)C5=C(C=CC=C5O)C4=O)C(O)=C23)C(C)=O
InChI
InChIKey=WYVYEIZFAUXWKW-SHUUXQFMSA-N
InChI=1S/C26H27NO10.ClH/c1-9-21(30)13(27)6-16(36-9)37-15-8-26(35,10(2)28)7-12-18(15)25(34)20-19(23(12)32)22(31)11-4-3-5-14(29)17(11)24(20)33;/h3-5,9,13,15-16,21,29-30,32,34-35H,6-8,27H2,1-2H3;1H/t9-,13-,15-,16-,21+,26-;/m0./s1
Carubicin (also known as Carminomycin) is an anthracycline antineoplastic antibiotic isolated from the bacterium Actinomadura carminata. Carubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. The drug is active against a variety of experimental tumors. Pharmacology studies in animals revealed that the drug bound largely to serum proteins and that it was widely distributed. In clinical trials The main toxic effect was myelosuppression but gastrointestinal intolerance and alopecia were also reported. Objective partial responses were seen in two of seven previously untreated patients with non-small cell lung cancer and one of three patients with squamous cell carcinoma of the head and neck previously untreated with chemotherapy.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Screening for new compounds with antiherpes activity. | 1984 Oct |
|
New TFO conjugates containing a carminomycinone-derived chromophore. | 2001 Jul-Aug |
|
Recent developments in the field of antitumour anthracyclines. | 2001 Jun |
|
[Cytotoxic activity of dammarane triterpenoids from birch leaves]. | 2002 Nov-Dec |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7227430
Initial clinical trials in the USSR used a twice weekly schedule for 3 weeks (total dose 27-40 mg/m 2) or daily x 5 courses repeated at 21-30-day intervals (1.5-5mg/m 2 per day)
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1594
Created by
admin on Fri Dec 15 15:35:05 GMT 2023 , Edited by admin on Fri Dec 15 15:35:05 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2110620
Created by
admin on Fri Dec 15 15:35:05 GMT 2023 , Edited by admin on Fri Dec 15 15:35:05 GMT 2023
|
PRIMARY | |||
|
m3140
Created by
admin on Fri Dec 15 15:35:05 GMT 2023 , Edited by admin on Fri Dec 15 15:35:05 GMT 2023
|
PRIMARY | Merck Index | ||
|
52794-97-5
Created by
admin on Fri Dec 15 15:35:05 GMT 2023 , Edited by admin on Fri Dec 15 15:35:05 GMT 2023
|
PRIMARY | |||
|
275649
Created by
admin on Fri Dec 15 15:35:05 GMT 2023 , Edited by admin on Fri Dec 15 15:35:05 GMT 2023
|
PRIMARY | |||
|
11570269
Created by
admin on Fri Dec 15 15:35:05 GMT 2023 , Edited by admin on Fri Dec 15 15:35:05 GMT 2023
|
PRIMARY | |||
|
C1582
Created by
admin on Fri Dec 15 15:35:05 GMT 2023 , Edited by admin on Fri Dec 15 15:35:05 GMT 2023
|
PRIMARY | |||
|
DTXSID30967253
Created by
admin on Fri Dec 15 15:35:05 GMT 2023 , Edited by admin on Fri Dec 15 15:35:05 GMT 2023
|
PRIMARY | |||
|
4V3R166MB3
Created by
admin on Fri Dec 15 15:35:05 GMT 2023 , Edited by admin on Fri Dec 15 15:35:05 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD